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THE 7-day cytotoxic lymphocytes (CWL) induced in
mixed lymphocyte culture express only the
chain of the interleukin-2 receptor (IL-2R). In the
present study this fact has been confirmed in a
murine semi-allogeneic system. The ability of low
doses of mafosfamide (Mf) to affect IL-2-induced
CTL proliferation has been demonstrated. It was
also shown that IL-2 activated resting suppressor
cells. The pretreatment of the suppressor cells
with either monoclonal antibodies (mAbs)
against the p75 chain of IL-2R, or with Mf abol-
ished the suppressive effect of these cells. No
restoration of the proliferative response occurred
when the anti-IL-2R mAb had been used. Flow
cytometry analysis of 7-day CTL was carried out
with mAbs against the and chains of IL-2R.
CTL treatment with Mf inhibited anti-IL-2R mAb
binding. It may be assumed that the anti-
proliferative effects of Mf which have been
demonstrated in this paper, were a result of
blocking the IL-2R chain.
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Introduction
Interleukin-2 (IL-2) is a T-cell derived lympho-
kine which participates in the manifestation of
the normal immune response. IL-2 exerts its bio-
logical activities b binding to a specific receptor
on a target cell. The IL-2 receptor (IL-2R) is
composed of at least three cell-surface proteins,
designated as the cz-, [3-, and ,-subunits. Different
combinations of these subunits can define a
number of states with differing affinities for IL-2
at the cell surface.- The interaction of IL-2 with its multi-subunit
receptor can be a target for drugs with immuno-
modulating activities. For adequate immuno-
correction it is very important to know what kind
of IL-2R chain is affected by the immunosuppres-
sive drug. For example, it has been shown that
lymphocytes treated in vitro with cyclosporin A
(CsA) show significant inhibition of the p55
chain (cz subunit) of IL-2R. 1-
Previously, our group has shown that the
spleen cells from mice of various genotypes have
a different susceptibility to the antiproliferative
action of alkylating agents.
14 The different sensi-
tivity of lymphoid cells from different strains of
mice to mafosfamide (a synthetic analogue of the
alkylating metabolites of cyclophosphamide), and
to the antiproliferative effects of cyclosporin A,.
has been also demonstrated. These interstrain
variations have not been related to the inhibition
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of interleukin 2 (IL-2) release but depend on dif-
ferences in the expression of the IL-2 receptor
(IL-2R). On the basis of these experiments we
considered that the J3 chain (p75) of IL-2R was a
possible target for mafosfamide (Mf) when admi-
nistered in doses which were relatively low but
sufficient for the inhibition of lymphocyte pro-
liferation.
To test this hypothesis we needed an experi-
mental system where the lymphoid cells expres-
sed only the [3 subunit of IL-2R. Two
experimental systems were used.
It is known that amongst cytotoxic lympho-
cytes (CTL) there exists a subset which expres-
ses the [3 chain but not the cz chain of IL-2R.
Our unpublished data show that within CTL
induced in a mixed lymphocyte culture, both cz
and [3 chains of IL-2R occur, but beginning on
the seventh day of cultivation the cells express
the p75 chain only. This seventh day CTL culture
was used as the first experimental system.
It is now evident that CD8+ cells reveal a
significantly greater number of binding sims for
anti-p75 than for anti-p55 monoclonal antibodies
(mAbs).7 Cell populations of thymocytes and
splenocytes with phenotype CD3 +, CD4-, CD8+
express IL-2RJ3.
s These data support the idea
that resting suppressor cells exist among normal
spleen cells and express the 3 chain of IL-2R.
This idea formed the basis of the second experi-
mental system.
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Material and Methods
Mice BAl/cJlac, DBA/2J, CC57BR/Mv, C57BL/6J,
and (C57BL/6 x DBA/2)F mice were obtained
from the Russian Academy of Medical Sciences
Care Units ’Stolbovaya’ and ’Rappolovo’
(CC57BR). Hybrids (BALB/c x CC57BR)F1 were
obtained from the vivarium of the Research
Centre for Medical Genetics. Male mice weighing
22-24 g were used.
Immunosuppressive agents: Mafosfamide (Asta
Z7654, Asta-Werke, Germany) and cyclosporin A
(Sandimiun, Sandoz, Switzerland) were used as
immunosuppressants.
Cell cultures: The isolation of lymphoid cells
from murine spleen and the inhibition of Con A-
induced lymphocyte proliferation by mafosfamide
(Mf) and cyclosporin A (CsA) have been descri-
bed in our previous publications.4’9 Briefly,
mice were killed by cervical dislocation. Lym-
phoid cells were isolated from the spleens,
washed, and resuspended in RPMI-1640 medium
(Flow tab., UK) supplemented with 10% horse
serum, 2 x 10-3 M HEPES, 2 mM t-glutamine, 2.8
x 10-6 M 2-mercaptoethanol, and 20 tg/ml gentami-
cin. Inhibition of Con-A stimulation by mafosfamide
or cyclosporin A was evaluated at six different con-
centrations within the dose ranges 0.1 30 tg/ml and
0.03 10 lg/ml, respectively. The cells were incu-
bated in fiat-bottomed 96-well plates (Nunc,
Denmark) with different concentrations of the drugs
for i h at 37C in humidified atmosphere containing
5% CO2. Then the plates were centrifuged, the super-
natants were washed away by Transtar-96 (Costar,
USA) and fresh culture medium with Con-A was
added. The control wells incubated without drugs
contained a culture medium with Con-A or culture
medium only. The cells were incubated for 72h,
pulsed with 40 kBq per well of [3H]-thymidine 4h
before the end of cultivation, harvested with a cell
harvester, and counted by using a liquid scintillation
counter.
Cytotoxic lymphocytes (CTL) were induced in
a semi-allogeneic mixed lymphocyte culture (Fig.
l(a)). When lymphocytes of C57BL/6 and DBA/2
mice were used as responding populations,
(C57BL/6 x DBA/2)F1 mice served as a source
of stimulator cells. The lymphocytes of (BALB/c
x CC57BR)F1 were used as stimulator cells for
the lymphocytes of BAU3/c and CC57BR mice.
Both the responder and stimulator cells (106
cells of each population) were co-cultivated for 7
days at 37C in a humidified atmosphere contain-
ing 5% CO2 in the wells (2 ml per well) of 24-
well plates (Nunc, Denmark). The cells were
washed twice and incubated for i h at a con-
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FIG. 1. Inhibition of CTL proliferative response (a) and suppressor
cell activity (b) with Mf treatment. Schemes of experiments (see
text).
centration of 2 x 105 cells per well in fiat-bot-
tomed 96-well plates with or without different
doses of Mf or CsA. Further, the cells were
washed again and cultivated under the same con-
ditions for 24h in the presence of 10 IU/ml of
recombinant IL-2 (rlL-2; Amersham, UK). Cell
proliferation was evaluated by [3H]-thymidine
incorporation.
Suppressor cells were activated by recombi-
nant IL-2 (rlL-2) treatment (Fig. l(b)). Spleen
cells were incubated in the presence of 10 IU of
rlL-2 (Sigma, USA) for 24 h. For the evaluation of
the suppressor activity, rlL-2-treated cells were
co-cultivated with the fresh isolated syngeneic
spleen cells in a ratio of 1:1. Co-cultivation of
normal cells with the cells incubated without rlL-
2 was used as a control. The cell mixture was sti-
mulated with Con A and incubated for 72 h. As a
result, the fresh isolated cells co-cultivated with
the cells incubated without rlL-2 showed aIL-2 receptor and mafosfamide
normal proliferative response to Con A. In con-
trast, the mixture of normal spleen cells and cells
preincubated with rIL-2 demonstrated a sig-
nificantl decreased response. The suppressor
cell sensitivity to Mf was evaluated by pretreating
the cells with different doses of the drug for an
hour. Then cells were washed and cultivated in
the presence of rlL-2 as described above.
Flow cytometry..a and J3 chains of IL-2R were
detected by an indirect immunofluorescence
method. A whole population of murine spleno-
cytes was used. IL-2Ra was detected by a mAb to
the IL-2R a chain (p55) (Becton & Dickinson,
USA). Monoclonal antibodies (Tm-l), specific
for the ] chain of IL-2R (p75), were a generous
gift from Dr T. Tanaka, Tokyo Metropolitan Insti-
tute of Medical Science. For indirect immuno-
fluorescent staining, 1.2 x 10 spleen cells were
washed three times with PBS containing 2% FCS
and were incubated for 30 min on ice with 100
!1 of monoclonal antibody diluted according to
the manufacturer’s instructions. Cells were
washed with PBS/FCS and treated under the
same conditions with FITC-labelled F(ab’)2-frag-
ments of rabbit anti-mouse Ig antibodies
(DAKOPATTS, Denmark). After washing with
PBS/FCS, cells were analysed by using flow cyto-
metry. An EPICS ’ELITE’ flow cytometer (Coulter,
USA) was used. At least 105 cells were analysed
and the data processed by means of the Multi-
Graph program (Coulter, USA).
Statistical analysis: Statistical comparisons were
performed using the Wilcoxon-Mann-Whitney’s
U criterion, paired Student’s t-test, and probit-
analysis for ED50 calculations.
Results
The influence ofMfand CsA on CTL: Mf strongly
suppressed the response of 7-day CTL to IL-2. In
cOntrast, CsA did not suppress IL-2 stimulated
CTL; nevertheless, we have shown a strong inhi-
bition of Con A-stimulated spleen cell prolifera-
tion at significantly lower doses. The inhibition of
IL-2-stimulated CTL with Mf was carried out in
the same dose range as the spleen cell pro-
liferative response induced with Con A (Fig. 2).
Thus, the cell sensitivities for DBA/2 and
C57BL//6 mice were significantly higher than
those for BALB/c and CC57BR (p < 0.05). It is
obvious that this model reveals the same inter-
strain differences as the experiments with the
freshly isolated Con A-stimulated spleen cells.
Blocking of the suppressor cell activity by mAbs
and Mf: The ability of IL-2 to stimulate sup-
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FIG. 2. Mf (A) and CsA (B) action on the proliferative response of
Con A-stimulated freshly isolated spleen cells or IL-2-stimulated
7-day CTL culture. [], spleen cells; N-x], cytotoxic lymphocytes.
pressor cells was demonstrated. Thus, the sig-
nifican decrease of the proliferative response
level was a result of co-cultivation of freshly iso-
lated Con A-stimulated murine spleen cells with
syngeneic lymphocytes preincubated with IL-2 for
24h (Figs. 3 and 4). The pretreatment of sup-
pressor cells with anti-p75 mAb restored the
normal lymphocyte response level. No restora-
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FIG. 3. Restoration of proliferative response to Con A decreased
by IL-2-stimulated suppressor cells with MF or anti-p75 mono-
clonal antibodies in DBA/2 mice. Proliferative response of spleen
cells cultivated without IL-2-stimulated cells is taken as 100%. *p
< 0.05.
tion of the proliferative response was demon-
strated with anti-p55 mAb. This level was also
increased after the pretreatment of suppressor
cells with low doses of Mf. The restoration of the
proliferative response was dose-dependent and
strain-specific. Our data demonstrated that expo-
sure of C57BL/6 cells to Mf at 0.1 l.tg/ml resulted
in the maximum increase of lymphocyte pro-
liferation. In BALB/c mice, a dose which ensured
a maximum level of restoration was ten times
higher than in C57BL/6 mice (see Fig. 4).
The influence ofMfon mAb binding with and
chains of IL-2R: The results obtained in this
study are shown in Fig. 5 which demonstrates
the binding of mAbs specific for a or [ chains of
IL-2R with 7-day CTL stimulated with rlL-2. The
cells analysed by flow cytometry were stained
with TM-[I but not with the IL-2R a-chain-spe-
cific mAb. Thus, we observed about 7% of TM-
[1
+ cells. It is necessary to bear in mind that the
whole population of splenocytes contains about
30% T cells. This means that 25% T cells were
TM-[I +. Our data show that Mf has a dose-
dependent effect on TM-[I antibody binding
(Fig. 5(a)). In addition, a nearly two-fold
decrease of the TM-I
+ cell level after the CTL
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FIG. 4. Different sensitivity of suppressor cells to Mf in BALB/c
(I-1) and C57BL/6 (/) mice (see text).
incubation with rIL-2 for 24 h was demonstrated.
These residual cells were also sensitive to Mf
treatment (Fig. 5(b)).
Discussion
Our results show that 7-day CTL express the [
chain but not the a chain of IL-2R (see Fig. 5).
Thus, in this study cells that expressed only con-
stitutive IL-2R were investigated. It was shown
that the exposure of CTL expressing the [ chain
of IL-2R to relatively low doses of Mf resulted in
a strong inhibition of the proliferative response
to IL-2, whereas these cells were insensitive to
the action of CsA. The different sensitivity of CTL
to Mf and CsA may be explained by the lack of a
specific target for CsA on 7-day CTL. The appear-
ance of the target (the p55 chain of IL-2R) on
the fresh isolated spleen cells stimulated with
Con-A makes these cells sensitive to the anti-
proliferative effect of CsA. The spleen cell
response to ConA was inhibited with the same
doses of Mf as was the CTL response to IL-2. The
experiments showed that both these cell popula-
tions revealed the same interstrain variations (see
Fig. 2).
Our data indicate the widely accepted opinion
that the mechanism of action of alkylating agents
is the result of DNA-DNA linkage,
2 but does notIL-2 receptor and mafosfamide
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FIG. 5. Flow cytometry analysis of CTL staining with mAbs spe-
cific to IL-2R (anti-p55, (F-I)) and IL-2R (anti-p75, (/)) before
and after treatment with Mf. The 7-day CTL (A) and 7-day CTL
incubated with rlL-2 during 24 h (B) were examined. The number
of labelled cells is presented as a percent of total spleen cells
counted.
explain completely the mechanisms of drug activ-
ity. It seems that the aforesaid mechanism is
important for the suppression of malignant cell
proliferation with high doses of alkylating drug,
when there is no other alternative but irreversible
damage to cell reproduction. In our case, the
alkylating drug plays the role of immune
response modifier but not the role of crucial
cytostatic. The present data indicate that Mf can
not only damage the proliferative response of
cells but can also restore it by means of sup-
pressor cell inhibition (see Figs. 3 and 4), it
being shown that the suppressor cell activation
was carried out by IL-2RI3. These data help to
explain the well-known fact that the suppressor
cells are a most sensitive subset to cyclophos-
phamide.
21-23
It should be noted that the increase in the
proliferative response was more visible in C57BL/
6 than in BALB/c mice (see Fig. 4). Previously, it
was shown that the constitutive IL-2R were
expressed in BALB/c mice clearly, whereas their
expression in C57BL/6 mice was poor.
15 These
data explain why Mf was able to affect cell sup-
pressor activity in C57BL/6 to a higher degree
than in BAtB/c mice.
In conclusion, our data suggest that the anti-
proliferative effect of Mf on lymphocytes acti-
vated with alloantigens or mitogens is a result of
blocking the IL-2R 3 chain. Thus, an additional
mode of action of alkylating drugs has been
shown.
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